International Clinical Psychopharmacology最新文献_第3页

Catatonia as a debut of systemic lupus erythematosus: a case report on a diagnostic challenge. 作为系统性红斑狼疮首发症状的紧张症：诊断难题的病例报告。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2024-11-19 DOI: 10.1097/YIC.0000000000000572

Helena Andreu, Blanca Serra-Sarró, Laura Bueno, Òscar de Juan, Iñaki Ochandiano, Luis Olivier, Helena Álvarez, Ailin Herrero, Cecilia Mantellini, Miguel Vicente, Maria Sagué-Vilavella, Lidia Ilzarbe, Luis Pintor, Marina Garriga, Vicent Llorca-Bofí, Miquel Bioque

引用次数: 0

A comparative study of the efficacy of venlafaxine and naltrexone for relapse prevention in patients with opioid use disorder attributed to tramadol. 文拉法辛和纳曲酮预防曲马多所致阿片类药物使用障碍患者复发的疗效比较研究。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2024-11-01 Epub Date: 2023-09-20 DOI: 10.1097/YIC.0000000000000487

Medhat M Bassiony, Nelly R Abdelfattah, Amany Elshabrawy, Mary M Adly

{"title":"A comparative study of the efficacy of venlafaxine and naltrexone for relapse prevention in patients with opioid use disorder attributed to tramadol.","authors":"Medhat M Bassiony, Nelly R Abdelfattah, Amany Elshabrawy, Mary M Adly","doi":"10.1097/YIC.0000000000000487","DOIUrl":"10.1097/YIC.0000000000000487","url":null,"abstract":"Tramadol and venlafaxine share similar pharmacological characteristics that may allow for overlapping therapeutic indications for them. The objective of this study was to compare the efficacy of venlafaxine and naltrexone in the treatment of tramadol abuse. This comparative trial included 95 patients with tramadol abuse who were detoxified for 2 weeks. Twenty-eight participants underwent the maintenance phase, while the remaining participants (n = 67) dropped out. The patients were randomized to use 50 mg/day of naltrexone or 225 mg/day of venlafaxine for 8 weeks. All participants were interviewed using SCID-I (DSM-IV-TR) criteria for diagnosing substance use and other psychiatric disorders. The proportion of relapsed patients was comparable between the naltrexone and venlafaxine groups (29.4% vs. 30.4%, P = 0.9). However, participants in the venlafaxine group stayed in treatment longer than participants in the naltrexone group, and the difference was significant (22.9 ± 7.89 days vs. 16.9 ± 3.4 days, P = 0.01). Only psychiatric comorbidity was found to be significantly associated with retention in treatment (80% vs. 22%, P = 0.005). Venlafaxine is as effective as naltrexone in preventing relapse in patients with tramadol abuse. Venlafaxine was more effective than naltrexone in treatment retention.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"341-349"},"PeriodicalIF":2.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41138050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

UK Medical Cannabis Registry: a case series analyzing clinical outcomes of medical cannabis therapy for generalized anxiety disorder patients. 英国医用大麻登记处：分析医用大麻治疗广泛性焦虑症患者临床疗效的病例系列。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2024-11-01 Epub Date: 2024-02-02 DOI: 10.1097/YIC.0000000000000536

Adam Li, Simon Erridge, Carl Holvey, Ross Coomber, Daniela Barros, Urmila Bhoskar, Matthieu Crews, Lorna Donnelly, Muhammad Imran, Laura Korb, Gracia Mwimba, Simmi Sachdeva-Mohan, James J Rucker, Mikael H Sodergren

{"title":"UK Medical Cannabis Registry: a case series analyzing clinical outcomes of medical cannabis therapy for generalized anxiety disorder patients.","authors":"Adam Li, Simon Erridge, Carl Holvey, Ross Coomber, Daniela Barros, Urmila Bhoskar, Matthieu Crews, Lorna Donnelly, Muhammad Imran, Laura Korb, Gracia Mwimba, Simmi Sachdeva-Mohan, James J Rucker, Mikael H Sodergren","doi":"10.1097/YIC.0000000000000536","DOIUrl":"10.1097/YIC.0000000000000536","url":null,"abstract":"This study aims to analyze changes in health-related quality of life (HRQoL) and safety in patients with generalized anxiety disorder (GAD) prescribed a homogenous selection of cannabis-based medicinal products (CBMPs). Patients prescribed Adven CBMPs (Curaleaf International, UK) for GAD were identified from the UK Medical Cannabis Registry. Primary outcomes were changes in patient-reported outcome measures (PROMs) from baseline up to 12 months, including GAD-7, Single-Item Sleep Quality Scale (SQS), and EQ-5D-5L. Adverse events were recorded using CTCAE version 4.0. A total of 120 patients were identified for inclusion, of which 38 (31.67%), 52 (43.33%), and 30 (25.00%) were prescribed oils, dried flower, and both formulations of CBMP. Associated improvements in GAD-7, SQS, and EQ-5D-5L at 1, 3, 6, and 12 months were observed compared to baseline ( P < 0.010). There were 24 (20.00%) patients who reported 442 (368.33%) adverse events, most of which were mild (n = 184, 41.63%) and moderate (n = 197, 44.57%). This study reports an association between initiation of a homogeneous CBMP therapy and improvements in anxiety severity and HRQoL in individuals with GAD. Moreover, therapy was well-tolerated at 12 months follow-up. Further investigation through randomized controlled trials will ultimately be required to determine causation.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"350-360"},"PeriodicalIF":2.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424060/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139650706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Venlafaxine for tramadol dependence and medical cannabis therapy for generalized anxiety disorder. 文拉法辛治疗曲马多依赖症和医用大麻治疗广泛性焦虑症。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2024-11-01 Epub Date: 2024-09-25 DOI: 10.1097/YIC.0000000000000567

Alessandro Serretti

引用次数: 0

Suicide in prison in the North of Italy (1993-2022): a case-control study examining differences between suicides inside and outside prison. 意大利北部监狱中的自杀事件（1993-2022 年）：一项病例对照研究，探讨监狱内外自杀事件的差异。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2024-10-09 DOI: 10.1097/YIC.0000000000000569

Raffaella Calati, Stefano Tambuzzi, Rosa Gravagnuolo, Livio Muscatiello, Maria Elena Magrin, Franca Crippa, Fabio Madeddu, Riccardo Zoja, Guendalina Gentile

{"title":"Suicide in prison in the North of Italy (1993-2022): a case-control study examining differences between suicides inside and outside prison.","authors":"Raffaella Calati, Stefano Tambuzzi, Rosa Gravagnuolo, Livio Muscatiello, Maria Elena Magrin, Franca Crippa, Fabio Madeddu, Riccardo Zoja, Guendalina Gentile","doi":"10.1097/YIC.0000000000000569","DOIUrl":"https://doi.org/10.1097/YIC.0000000000000569","url":null,"abstract":"Prisoners constitute a group at suicide risk, showing higher relative rates of suicides than the general population. However, there is limited knowledge about the characteristics of those who die by suicide in Italian prisons. Based on the total sample of suicides of the Institute of Forensic Medicine of Milan (1993-2022), suicides in prison (N = 120) were matched by age and gender with cases that occurred outside prison (N = 300) and compared with them. The considered variables were sociodemographic, clinical, and suicide-related. Univariate analyses and logistic regression model were performed. In univariate analyses, suicides in prison showed higher rates of ethnicity different from white Caucasian, lower rates of depression, higher rates of alcoholism, addiction, respiratory system diseases, hepatitis, and amyotrophic lateral sclerosis, lower use of any medication, and in particular psychotropic medications, and a higher percentage of violent suicide method versus nonviolent compared to suicides outside prison. In the logistic regression model, ethnicity, depression, and addiction were the only features differentiating suicides in prison from ones outside prison. Particular attention should be paid to inmates with non-white ethnicity and those with addiction. Ensuring adequate access to psychiatric care and implementing comprehensive suicide prevention strategies within Italian prisons is crucial.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142390343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cariprazine as a maintenance treatment in dual schizophrenia: a 6-month observational study in patients with schizophrenia and cannabis use disorder. 卡哌嗪作为双重精神分裂症的维持治疗：对精神分裂症和大麻使用障碍患者进行的为期 6 个月的观察研究。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2024-09-25 DOI: 10.1097/YIC.0000000000000568

Nestor Szerman, Pablo Vega, Carlos Roncero, Lola Peris, Lara Grau-López, Ignacio Basurte-Villamor

{"title":"Cariprazine as a maintenance treatment in dual schizophrenia: a 6-month observational study in patients with schizophrenia and cannabis use disorder.","authors":"Nestor Szerman, Pablo Vega, Carlos Roncero, Lola Peris, Lara Grau-López, Ignacio Basurte-Villamor","doi":"10.1097/YIC.0000000000000568","DOIUrl":"https://doi.org/10.1097/YIC.0000000000000568","url":null,"abstract":"Schizophrenia is often associated with substance use disorders, particularly cannabis use disorder (CUD). However, treatments frequently fail to address both conditions simultaneously. This study aimed to evaluate the antipsychotic effectiveness of cariprazine in patients with both schizophrenia and CUD in a real-world setting. A 6-month observational study was conducted on 58 patients diagnosed with schizophrenia and CUD, treated with cariprazine. Antipsychotic effectiveness was measured using the Positive and Negative Syndrome Scale and the Clinical Global Impression-Schizophrenia Scale, along with the Improvement and Severity scales. Cannabis consumption and addiction severity were assessed using the Cannabis Abuse Screening Test and the Severity of Dependence Scale, while functioning was evaluated with the Sheehan Disability Inventory. Cariprazine treatment resulted in significant improvements in schizophrenia symptoms (Positive and Negative Syndrome Scale change: -47.88 points, P < 0.0001; Clinical Global Impression-Schizophrenia Scale change: -8.26 points, P < 0.0001). Cannabis use and dependence also decreased (Cannabis Abuse Screening Test change: -7.0 points, P < 0.0001; Severity of Dependence Scale change: -7.88 points, P < 0.0001), alongside improvements in functioning (Sheehan Disability Inventory change: -9.48 points, P < 0.0001). These results suggest that cariprazine is effective for both schizophrenia and CUD, though further research is needed to confirm these findings.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The impact of efficacy of long-acting injectable antipsychotics on caregivers' burden of patients with schizophrenia. 长效注射抗精神病药物的疗效对精神分裂症患者护理负担的影响。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2024-02-22 DOI: 10.1097/YIC.0000000000000539

Enrico Capuzzi, Cecilia Quitadamo, Alice Caldiroli, Massimo Clerici, Massimiliano Buoli

引用次数: 0

The effect of early or late initiation of long-acting antipsychotics on the caregiver burden in schizophrenia. 早或晚服用长效抗精神病药物对精神分裂症患者照顾者负担的影响。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2023-11-23 DOI: 10.1097/YIC.0000000000000524

Dilara Çırakman, Ersin Hatice Karslıoğlu, Neşe Burcu Bal, Ali Çayköylü

{"title":"The effect of early or late initiation of long-acting antipsychotics on the caregiver burden in schizophrenia.","authors":"Dilara Çırakman, Ersin Hatice Karslıoğlu, Neşe Burcu Bal, Ali Çayköylü","doi":"10.1097/YIC.0000000000000524","DOIUrl":"10.1097/YIC.0000000000000524","url":null,"abstract":"The effective treatment in the early stages of schizophrenia is of critical importance to improve the prognosis. Schizophrenia affects patients' relatives too. The effects of early or late initiation of long-acting injectable antipsychotics (LAI-APs) on the patient have been shown, yet their effects on the caregiver are still unknown. We aimed to determine how the time of initiation of LAI-APs affects the caregiver burden by comparing the patients who were started on LAI-APs in the first 5 years of diagnosis and those who were started at a later period. Patients were classified as 'early-LAI' and 'late-LAI' according to the time of initiation of a LAI-AP. Their caregivers were also classified as the same way, as 'caregiver-early' and 'caregiver-late' and were compared in terms of caregiver burden. The quality of life, depression, anxiety, and caregiver burden scores of the caregiver-late group were significantly worse. The time of initiation of LAI-APs and the functioning levels of the patients were found to be determinant factors for the caregiver burden. This is the first study to investigate the effects of LAI-AP's initiation time on the caregivers to our knowledge. The use of LAI-APs in the early stages is associated with better outcomes for the caregiver.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"313-322"},"PeriodicalIF":2.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138046809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Type 2 diabetes mellitus is associated with manic morbidity in elderly patients with mood disorders. 2型糖尿病与老年情绪障碍患者的躁狂发病率有关。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2023-10-21 DOI: 10.1097/YIC.0000000000000515

Francesco Weiss, Giulio Emilio Brancati, Camilla Elefante, Alessandra Petrucci, Teresa Gemmellaro, Lorenzo Lattanzi, Giulio Perugi

{"title":"Type 2 diabetes mellitus is associated with manic morbidity in elderly patients with mood disorders.","authors":"Francesco Weiss, Giulio Emilio Brancati, Camilla Elefante, Alessandra Petrucci, Teresa Gemmellaro, Lorenzo Lattanzi, Giulio Perugi","doi":"10.1097/YIC.0000000000000515","DOIUrl":"10.1097/YIC.0000000000000515","url":null,"abstract":"The association between mood disorders, especially bipolar disorder (BD), and metabolic disorders, is long known. However, to which extent metabolic disorders affect the course of mood disorders in late life is still open to inquiring. To assess the impact of type 2 diabetes mellitus (T2DM) on late-life mood disorders a retrospective chart review was performed. Elderly depressive patients (≥ 65 years) diagnosed with Major Depressive Disorder (N = 57) or BD (N = 43) and followed up for at least 18 months were included and subdivided according to the presence of T2DM comorbidity. Vascular encephalopathy (39.1% vs. 15.6%, P = 0.021) and neurocognitive disorders (21.7% vs. 5.2%, P = 0.028), were more frequently reported in patients with T2DM than in those without. Patients with T2DM showed a greater percentage of follow-up time in manic episodes (r = -0.23, P = 0.020) and a higher rate of manic episode(s) during follow-up (21.7% vs. 5.2%, P = 0.028) than those without. When restricting longitudinal analyses to patients with bipolar spectrum disorders, results were confirmed. In line with the well-known connection between BD and metabolic disorders, our data support an association between T2DM and unfavorable course of illness in the elderly with BD.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"294-304"},"PeriodicalIF":2.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41199836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Towards a replicable protocol to identify patients with psychiatric disorders at higher risk of developing dementia. 制定一个可复制的方案，以识别罹患痴呆症风险较高的精神障碍患者。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2024-09-01 Epub Date: 2024-02-13 DOI: 10.1097/YIC.0000000000000542

Veronika Matuskova, Martin Vyhnalek

引用次数: 0